Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Zimmer Biomet readies $1B tenders for senior debt
Zimmer Biomet said today that it plans to float tender offers for some $1.1 billion worth of senior notes. The tenders are aimed at lowering the debt load it took on when Zimmer merged with Biomet last year.
The Warsaw, Ind.-based orthopedics giant said it plans to buy and cancel its 5.75% senior notes due 2039, its 4.45% senior notes due 2045, its 4.25% senior notes due 2035, its 3.55% senior notes due 2025 and its 4.625% senior notes due 2019. The actual yields are slated to be determined Dec. 6, with a settlement date of Dec. 13, Zimmer Biomet said. Read more
4. NeuroStar launches real-world registry for TMS therapy in depression
Transcranial magnetic stimulation device developer NeuroStar said today it launched a real-world registry for patients with depression treated with TMS therapy, touting it as the largest registry of its kind to date.
The registry looks to collect and analyze data from over 6,000 patients with major depressive disorder who have been treated with NeuroStar Advanced Therapy to better understand outcomes and usefulness of the therapy in a clinical setting. Read more
3. Veith 2016 Roundup: Stent grafts take center stage
Medtronic touted data from a series of sub-group analyses from the 10-year 1,200-patient Engage study of its Endurant II and Endurant IIs stent grafts for treating abdominal aortic aneurysms last week at the annual Veith Symposium on vascular disease.
First-time results from a review of the occurrence of endoleaks at the aneurysm neck, presented by Dr. Hence Verhagen of Erasmus University Medical Center in Rotterdam, Holland, showed a 97.8% rate of freedom from Type Ia endoleaks at 1 year. The rate was 97.3% at 2, 96.7% at 3 years and 96% at 4 years. Read more
2. Monteris Medical raises $7m for NeuroBlate
Monteris Medical raised nearly $7 million of a hoped-for $10 million debt-and-options round for the NeuroBlate neurosurgery device it’s developing.
Plymouth, Minn.-based Monteris last month won FDA approval for an investigational device exemption trial of NeuroBlate in patients newly diagnosed with a form of brain cancer called glioblastoma multiforme. The MRI-guided device is designed to ablate, necrotize or coagulate soft tissue during neurosurgery procedures using laser thermotherapy. Read more
1. Intarcia seeks FDA nod for Medici drug delivery system
Intarcia Therapeutics said today that it submitted a New Drug Application to the FDA for its injection-free ITCA 650 candidate, the 1st drug to use Intarcia’s Medici drug delivery system to treat Type II diabetes. The ITCA 650 enables subcutaneous delivery of exenatide using a match-sized osmotic pump placed under the skin in an in-office procedure.
With the NDA submission, the Boston-based company triggered a 3rd, $100 million milestone payment from the $300 million royalty financing put in place in the 2nd quarter of 2015. The milestone payment adds to the $215 million Intarcia raised in September. Read more
